vertex pharmaceuticals

M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE...

Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...

Morgan Stanley has lowered the price target on Vertex Pharmaceuticals (NASDAQ: VRTX) from $33 to $32 and maintains its Underweight rating.

Piper Jaffray is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), maintaining Overweight. In a note to clients, Piper Jaffray writes, "Vertex reported positive 48-week STRIVE data for VX-770 in patients with Cystic Fibrosis with the G551D mutation. Previously reported lung...

J.P. Morgan is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), raising its PT from $46 to $53. In a note to clients, J.P. Morgan writes, "Overall, we view Incivek pricing as an upside surprise but one that was widely anticipated by the market, and, at the end of the day, the...

According to Bank of America, Vertex Pharmaceuticals (NASDAQ: VRTX) will capture the full value of Incivek therapy in 1 quarter vs 3 quarters for MRK, so the dollar market share for VRTX with our assumptions is significantly higher at 70-80%. Bank of America said that with the recent FDA approvals...

JP Morgan has raised the price target on Vertex Pharmaceuticals (NASDAQ: VRTX) from $46 to $53 and maintains its Neutral rating.

Morgan Stanley is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), maintaining Underweight. In a note to clients, Morgan Stanley writes, "Merck's boceprevir received FDA approval Friday, roughly on schedule but ahead of the expectations of more bullish Vertex investors who...

J.P. Morgan is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), reiterating Neutral. In a note to clients, J.P. Morgan writes, "VRTX shares are up 20% since FDA briefing documents were released for telaprevir in late April; this was driven by expectations that approval of...

Piper Jaffray is out with its report on Vertex Pharmaceuticals (NASDAQ: VRTX), maintaining Overweight. In a note to clients, Piper Jaffray writes, "On Friday 5/13, Merck received approval for VICTRELIS in combination with peginterferon alfa and ribavirin for the treatment of chronic HCV genotype 1...

Piper Jaffray is out with its report today on Hallmark Financial (NASDAQ: HALL), downgrading HALL from Overweight to Neutral. In a note to clients, Piper Jaffray writes, "Hallmark's first quarter results reflect an increasingly difficult to manage Florida book of non-standard auto business and...

Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported 1Q11 revenues of $74mn, “above our estimate of $18mn and consensus of $25mn due to a one time $50mn milestone,” Goldman Sachs reports. “Total opex of $234mn was below our estimate of $248mn, driven primarily by lower R&D,” Goldman Sachs...

J.P. Morgan is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), maintaining Neutral. In a note to clients, J.P. Morgan writes, "We remain very impressed by VX-770 in the G551D CF population and together with Class 4/5 CF patients, we estimate a peak opportunity approaching $1B...